Opus Genetics, Inc

Industry

  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
    • Specialty Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy

Other Names/Subsidiaries

  • Ocuphire Pharma
  • Rexahn Pharmaceuticals
See more in Biomedtracker

Latest on Opus Genetics, Inc

Scrip

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Opus Genetics has reported positive topline results from VEGA-3, its second pivotal Phase III trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. It now plans to f

In Vivo

In Conversation With Foundation Fighting Blindness

 
• By David Wild

Since its inception 53 years ago, the Foundation Fighting Blindness (FFB) has deployed nearly $1bn to advance treatments for inherited retinal diseases and age-related macular degeneration. Under CEO

Scrip

Ocuphire/Opus Merger Creates Public Retinal Gene Therapy Firm

 
• By Joseph Haas

Ocuphire Pharma Inc. and privately held Opus Genetics Inc. announced an all-stock merger on 22 October that will create a publicly traded company focused primarily on gene therapies for inherited reti

Scrip

Orasis Prepares To Battle AbbVie In Presbyopia

 
• By Joseph Haas

AbbVie Inc. will have direct competition for its presbyopia product Vuity, since privately held Orasis Pharmaceuticals Ltd. got US Food and Drug Administration approval for the same indication on 1